Literature DB >> 10506670

Nerve constriction in the rat: model of neuropathic, surgical and central pain.

G M Pitcher1, J Ritchie, J L Henry.   

Abstract

In preparation for a series of electrophysiological experiments in a model of neuropathic pain, the present spinal reflex study was done to determine the optimal time after sciatic nerve constriction in the rat for tactile allodynia and to determine also the appropriate 'control' for the nerve constriction model. Therefore, this study focused on the magnitude and time course of change in paw withdrawal threshold following unilateral sciatic nerve constriction in the rat. Male Sprague-Dawley rats (375-425g) were used. Nerve constriction was done by placing a 2 mm polyethylene cuff (PE-90) around the left sciatic nerve (n=8). A second group of rats (n=8) received unilateral sham surgery and a third group (n=8) was unoperated. The ipsi- and contralateral hind paw withdrawal thresholds in each of the 3 groups were measured using von Frey hairs. In unoperated rats, the withdrawal threshold of each of the hind paws remained unchanged at approximately 50 g throughout the entire time course of the study, which lasted 145 days. However, in cuff-implanted rats, the withdrawal threshold of the nerve-injured hind paw decreased as soon as 1 day after surgery, reached as low as 1 to 2 g by 5 days and remained low throughout the test period. Threshold in sham-operated rats showed a bilateral decrease starting on days 1-3, which stabilised at about 30 g until about day 40, after which values returned gradually toward the unoperated withdrawal thresholds. In nerve-constricted rats the withdrawal threshold of the hind paw contralateral to the cuff followed the same change seen in sham-operated rats until about day 37, after which the withdrawal threshold matched that of the cuff-implanted hind paw. The data show that the cuff-induced sciatic nerve constriction produces a sustained hypersensitivity to normally innocuous tactile sensory input and that a relatively constant ipsilateral mechanical hyperalgesia can be found from days 5-27. It is also demonstrated that the contralateral hind paw and either hind paw in sham-operated rats are inappropriate as 'controls'. The data in this study suggest that three distinct types of allodynia are expressed. Ipsilateral allodynia may be representative of a model of neuropathic pain. The contralateral allodynia may be a model of central pain, as it likely arises from changes in central sensory processing. Allodynia in sham-operated rats was also expressed bilaterally and may be a model of long-term postoperative pain.

Entities:  

Mesh:

Year:  1999        PMID: 10506670     DOI: 10.1016/s0304-3959(99)00085-8

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  31 in total

1.  Response to Protocol Review Scenario: Request for more information.

Authors:  Michele M Bailey; Michelle Loh
Journal:  Lab Anim (NY)       Date:  2016-01       Impact factor: 12.625

2.  Painful peripheral nerve injury decreases calcium current in axotomized sensory neurons.

Authors:  J Bruce McCallum; Wai-Meng Kwok; Damir Sapunar; Andreas Fuchs; Quinn H Hogan
Journal:  Anesthesiology       Date:  2006-07       Impact factor: 7.892

3.  Bilateral changes of cannabinoid receptor type 2 protein and mRNA in the dorsal root ganglia of a rat neuropathic pain model.

Authors:  Ivana Hradilová Svízenská; Václav Brázda; Ilona Klusáková; Petr Dubový
Journal:  J Histochem Cytochem       Date:  2013-05-08       Impact factor: 2.479

4.  Bilateral activation of glial cells and cellular distribution of the chemokine CCL2 and its receptor CCR2 in the trigeminal subnucleus caudalis of trigeminal neuropathic pain model.

Authors:  Lucie Kubíčková; Ilona Klusáková; Petr Dubový
Journal:  Histochem Cell Biol       Date:  2020-02-04       Impact factor: 4.304

5.  Peripherally Selective Cannabinoid 1 Receptor (CB1R) Agonists for the Treatment of Neuropathic Pain.

Authors:  Herbert H Seltzman; Craig Shiner; Erin E Hirt; Anne F Gilliam; Brian F Thomas; Rangan Maitra; Rod Snyder; Sherry L Black; Purvi R Patel; Yatendra Mulpuri; Igor Spigelman
Journal:  J Med Chem       Date:  2016-08-10       Impact factor: 7.446

6.  Relationship of axonal voltage-gated sodium channel 1.8 (NaV1.8) mRNA accumulation to sciatic nerve injury-induced painful neuropathy in rats.

Authors:  Supanigar Ruangsri; Audrey Lin; Yatendra Mulpuri; Kyung Lee; Igor Spigelman; Ichiro Nishimura
Journal:  J Biol Chem       Date:  2011-09-30       Impact factor: 5.157

7.  Early dexamethasone treatment after implantation of a sciatic-nerve cuff decreases the concentration of substance P in the lumbar spinal cord of rats with neuropathic pain.

Authors:  Francis Beaudry; Christiane Girard; Pascal Vachon
Journal:  Can J Vet Res       Date:  2007-04       Impact factor: 1.310

8.  Mu-opioid receptors are not necessary for nortriptyline treatment of neuropathic allodynia.

Authors:  Yohann Bohren; Dzenan Karavelic; Luc-Henri Tessier; Ipek Yalcin; Claire Gavériaux-Ruff; Brigitte L Kieffer; Marie-José Freund-Mercier; Michel Barrot
Journal:  Eur J Pain       Date:  2009-12-28       Impact factor: 3.931

9.  Peripheral nerve injury and TRPV1-expressing primary afferent C-fibers cause opening of the blood-brain barrier.

Authors:  Simon Beggs; Xue Jun Liu; Chun Kwan; Michael W Salter
Journal:  Mol Pain       Date:  2010-11-02       Impact factor: 3.395

10.  A New Population of Parvocellular Oxytocin Neurons Controlling Magnocellular Neuron Activity and Inflammatory Pain Processing.

Authors:  Marina Eliava; Meggane Melchior; H Sophie Knobloch-Bollmann; Jérôme Wahis; Miriam da Silva Gouveia; Yan Tang; Alexandru Cristian Ciobanu; Rodrigo Triana Del Rio; Lena C Roth; Ferdinand Althammer; Virginie Chavant; Yannick Goumon; Tim Gruber; Nathalie Petit-Demoulière; Marta Busnelli; Bice Chini; Linette L Tan; Mariela Mitre; Robert C Froemke; Moses V Chao; Günter Giese; Rolf Sprengel; Rohini Kuner; Pierrick Poisbeau; Peter H Seeburg; Ron Stoop; Alexandre Charlet; Valery Grinevich
Journal:  Neuron       Date:  2016-03-03       Impact factor: 17.173

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.